BioKangtai(SZ:300601) Xin Lang Cai Jing·2026-01-07 01:29Group 1 - The core viewpoint of the news is that 康泰生物 (Kangtai Biological) is experiencing fluctuations in its stock performance and financing activities, with a notable decrease in net profit despite a slight increase in revenue [1][2]. Group 2 - On January 6, 康泰生物's stock rose by 0.33%, with a trading volume of 166 million yuan. The financing buy amount was 13.33 million yuan, while the financing repayment was 22.44 million yuan, resulting in a net financing buy of -9.12 million yuan [1]. - As of January 6, the total balance of margin trading for 康泰生物 was 741 million yuan, with a financing balance of 735 million yuan, accounting for 4.27% of the circulating market value, which is below the 10% percentile level over the past year [1]. - In terms of securities lending, 康泰生物 repaid 9,100 shares and sold 27,400 shares on January 6, with a selling amount of 421,700 yuan. The remaining securities lending volume was 427,000 shares, with a balance of 6.57 million yuan, which is above the 60% percentile level over the past year [1]. Group 3 - As of September 30, 康泰生物 had 63,400 shareholders, an increase of 3.15% from the previous period, while the average circulating shares per person decreased by 2.99% to 14,196 shares [2]. - For the period from January to September 2025, 康泰生物 achieved an operating income of 2.063 billion yuan, a year-on-year increase of 2.24%, but the net profit attributable to the parent company was 49.16 million yuan, a significant decrease of 86% [2]. - Since its A-share listing, 康泰生物 has distributed a total of 1.765 billion yuan in dividends, with 525 million yuan distributed over the past three years [2]. - Among the top ten circulating shareholders as of September 30, 2025, 易方达创业板ETF (E Fund ChiNext ETF) held 13.20 million shares, a decrease of 2.22 million shares from the previous period, while 香港中央结算有限公司 (Hong Kong Central Clearing) increased its holdings by 3.29 million shares to 7.99 million shares [2].